Nexalin Technology Announced Regulatory Approval to Sell Gen 2 SYNC, 15 mA Neurostimulation DIFS™ Device in Israel
On October 30, 2025, Nexalin Technology, Inc., a company recognized for its Deep Intracranial Frequency Stimulation (DIFS™) technology, announced that its Gen-2 Console (“SYNC”) 15 mA neurostimulation device received regulatory approval for commercial sale in Israel from the Israeli Ministry of Health.
The company had been designing and developing neurostimulation systems to address the global rise in mental health conditions. Nexalin’s products were believed to be non-invasive, not perceptible to the patient, and intended to provide the...